Details

Autor(en) / Beteiligte

• Ozturk, S.
• Cetin, D. G.
• Cetin, M.
• Yilmaz, M. D.
• Ozler, T. E.
• Cebeci, E.
• Karadag, S.
• Feyizoglu, H.
• Bahat, Gulistan

Titel

Prevalence and Associates of Frailty Status in Different Stages of Chronic Kidney Disease: A Cross-Sectional Study

Ist Teil von

• The Journal of nutrition, health & aging, 2022-09, Vol.26 (9), p.889-895

Ort / Verlag

Paris: Springer Paris

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Objectives Frailty is a state of homeostenosis associated with adverse outcomes. Chronic kidney disease (CKD) increases considerably by aging and shares the common risk factors with frailty. We aimed to examine the prevalence and independent associates of frailty status in CKD patients. Design In this single-centre, cross-sectional study, we used the five-item Fatigue, Resistance, Ambulation, Illnesses and Loss of Weight (FRAIL) scale to evaluate frailty. A binary logistic regression analysis model including the parameters found to have relationship with frailty in univariate analyses was used to detect independent associates of frailty status. Odds ratio (OR) and 95% confidence interval (CI) were given. Participants Study included 148 patients aged 18–80. Sixty (60) patients were end stage renal disease (ESRD) patients on maintenance hemodialysis (HD) (at least for 3 months) and 88 were stage 3–4 CKD patients. Thirty-seven ( 37 ) patients (42%) were eGFR G3a, 31 patients (35.3%) were eGFR G3b and 20 patients (22.7%) were eGFR G4 in stage 3–4 CKD patients. Measurements Demographics, etiology of CKD, comorbidities, regular drugs, dialysis-related and laboratory data were recorded. FRAIL scale was scored as follows; 0=robust, 1–2=prefrail, and ≥3=frail. The frailty status was compared between frail+prefrail group vs robust (non-frail) group. Results The prevalences of prefrailty and frailty were 68.3% and 3.3% in HD group and 53.4% and zero in stage 3–4 CKD group, respectively (p = 0.025). In the multivariate logistic regression analysis, being in HD group (OR=3.87, 95% CI= 1.06–14.19, p=0.04), older age (OR=1.09, 95% CI= 1.04–1.13) and female sex (OR=9.13, 95% CI= 2.82–29.46) were independent risk factors for frailty (p<0.001, for both). Conclusion Prefrailty and frailty are quite common among HD and CKD stage 3–4 patients. Being an HD patient is an independent risk factor for non-robust (frail or prefrail) status. Our findings point out a remarkably high prevalence of frailty severity (prefrailty/frailty) phenotype among patients with advanced CKD stages.